Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Inclusion Criteria:

• Patients must have histologically documented history of large B-cell lymphoma,including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primarymediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arisingfrom follicular lymphoma.

• Adult males or females must be of age ≥18 years or older at time of signing informedconsent.

• Patients must be capable of understanding the protocol with willingness to complywith all study procedures including availability for the duration of the study.

• Patients must be able to understand and willing to sign a written informed consentform (ICF) document.

• Measurable PET/CT positive disease (partial response or stable disease per the 2014Lugano Classification) on PET/CT obtained at least 21 days after, but no more than 60 days after CAR-T with axicabtagene-ciloleucel.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

• Participants must have adequate organ and bone marrow function.

• Patients must have adequate hepatic function.

• Patients must have adequate renal function.

• Baseline Oxygen Saturation >92% on room air.

• Females of reproductive potential must avoid pregnancy for at least 4 weeks beforebeginning lenalidomide therapy, during therapy, during dose interruptions and for atleast 4 weeks after completing therapy. Females must commit either to abstaincontinuously from heterosexual sexual intercourse or to use two methods of reliablebirth control, beginning 4 weeks prior to initiating treatment with lenalidomide,during therapy, during dose interruptions and continuing for 4 weeks followingdiscontinuation of lenalidomide therapy.

Exclusion Criteria:

• Patients who are currently receiving or who have received any investigational studyagent ≤4 weeks prior to the screening visit are ineligible.

• Detectable cerebrospinal fluid malignant cells, brain metastases, or active centralnervous system (CNS) lymphoma after CAR T cell administration.

• History or presence of CNS disorder, such as seizure disorder, cerebrovascularischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease withCNS involvement.

• Presence of bacterial, viral, fungal, and/or other infection of any origin that isuncontrolled and/or requires intravenous (IV) antimicrobials for treatment.

• Known cardiac atrial or cardiac ventricular lymphoma involvement.

• History of symptomatic pulmonary embolism within 6 months of enrollment.

• Known primary immunodeficiency.

• History of autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemiclupus) resulting in end organ injury or requiring systemicimmunosuppression/systemic disease modifying agents within the last 2 years.

• History of hypersensitivity, allergy or severe skin reactions to lenalidomide (e.g.,angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis).

• History of hypersensitivity, allergy or previous exposure to tafasitamab.

• Any medical condition deemed by the treating physician likely to interfere withassessment of safety or efficacy of study treatment.